Reporting and Interpreting Results
LESLEIGH S ABBOTT , ELIZABETH A EISENHAUER , LESLEY K SEYMOUR
Phase I Cancer Clinical Trials: A Practical Guide 308 -308
2015
Anti-cancer agents
Lesley K SEYMOUR
Current pharmaceutical design 8 ( 25)
2002
Modulation of the biologic behaviour of breast cancer; in vitro models and clinical correlates
Lesley Katie Seymour
1999
iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics
MD Lesley Seymour , Jan Bogaerts , Lawrence H Schwartz
Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?
Penelope Bradbury , Lesley Seymour
Cancer Journal 15 ( 5) 354 -360
13
2009
Tarceva™ (erlotinib) exposure/effects (EE) analysis from a Phase III study in advanced NSCLC: Effect of smoking on the PK of erlotinib
Denni Zborowski , Marta Hamilton , Ashok Rakhit , Jianfeng Lu
Cancer Research 65 1451 -1451
17
2005
Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models
Theodora Voskoglou-Nomikos , Lesley Seymour , Joseph L. Pater
Clinical Cancer Research 9 ( 11) 4227 -4239
805
2003
A Pharmacodynamic Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Metastatic Colorectal Cancer Patients
Gerald Batist , Holger W. Hirte , Glenwood Goss , Pierre Major
Clinical Cancer Research 9 ( 7) 2457 -2464
54
2003
Epidermal growth factor receptor inhibitors: an update on their development as cancer therapeutics.
Lesley Seymour
Current opinion in investigational drugs 4 ( 6) 658
11
2003
Controversies in the design of phase II clinical trials.
Lesley Seymour
Clinical advances in hematology & oncology 8 ( 2) 95
2010
Gemcitabine P lus V inorelbine C ompared W ith C isplatin P lus Vinorelbine o r C isplatin P lus G emcitabine f or A dvanced N on- Small-Cell L ung C ancer: A P hase I II T rial o f t he I talian GEMVIN I nvestigators a nd t he N ational C ancer I nstitute o f Canada C linical T rials G roup
Francovito Piantedosi , Sergio Federico Robbiati , Santi Barbera , Ciro Gallo
329
2003
Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients
Frances A Shepherd , Frances A Shepherd , Stefan Michiels , Elisabeth Brambilla
Translational lung cancer research 10 ( 2) 826 -838
2021
A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].
Stephen KL Chia , Philippe L Bedard , John Hilton , Eitan Amir
Journal of Clinical Oncology 36 1029 -1029
13
2018
A Randomized Phase II study of Reolysin in Patients with Previously Treated Advanced or Metatstatic Non Small Cell Lung Cancer (NSCLC) receiving Standard Salvage Chemotherapy – Canadian Cancer Trials Group IND 211.
Donald Morris , Dongsheng Tu , Mustapha Ali Tehfe , Garth Andrew Nicholas
Journal of Clinical Oncology 34
3
2016
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
Glenwood D. Goss , Andrew Arnold , Frances A. Shepherd , Mircea Dediu
Journal of Clinical Oncology 28 ( 1) 49 -55
206
2010
Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
Charles A. Butts , Keyue Ding , Lesley Seymour , Philip Twumasi-Ankrah
Journal of Clinical Oncology 28 ( 1) 29 -34
272
2010
Association of the 15q25 and 5p15 Lung Cancer Susceptibility Regions with Gene Expression in Lung Tumor Tissue
Gord Fehringer , Geoffrey Liu , Melania Pintilie , Jenna Sykes
Cancer Epidemiology, Biomarkers & Prevention 21 ( 7) 1097 -1104
17
2012
Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group
Natasha B. Leighl , Raymond Ng , Baktiar Hasan , Nicole Mittmann
Journal of Clinical Oncology 25 ( 16) 2256 -2261
41
2007
Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Andrea Bezjak , Dongsheng Tu , Lesley Seymour , Gary Clark
Journal of Clinical Oncology 24 ( 24) 3831 -3837
265
2006
Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10
Carmela Pepe , Baktiar Hasan , Timothy L. Winton , Lesley Seymour
Journal of Clinical Oncology 25 ( 12) 1553 -1561
184
2007